Mitomycin-C in the therapy of far-advanced malignant tumors

Abstract

Forty-six patients with far-advanced malignancies, primarily of epithelial origin, were treated with intravenously administered mitomycin-C over a 4-year period. Several patients received more than one course of therapy. Thirty per cent of the patients demonstrated a transient, objective remission as evidenced by regression or disappearance of tumor masses. A significant remission of 7 and 15 months was observed in 2 patients. Dosages of 100 μ/per kg daily or 125 μ/per kg semiweekly were selected as effective and relatively nontoxic. No irreversible toxic effects were encountered. These pertinent studies have produced sufficient degree of confidence in the safety and effectiveness of the drug as to warrant a more extensive exploration of its usefulness in the field of cancer chemotherapy.